SlideShare une entreprise Scribd logo
1  sur  4
Télécharger pour lire hors ligne
Pakistan’s Regulatory Approach
Can Quality of Drug be assured through Testing in Government Laboratories?
Obaid Ali & Roohi B. Obaid
Planting quality in manufacturing of drugs and its secure delivery to the patient is a real challenge and remains a
concern all around. Inability of the intellectuals and Government leadership (Federal Government, generally
Provincial Governments and particularly the Punjab Government) to understand the phenomenon of drug quality
is certainly amazing and a reason of great distress for real professionals. It is considered that drugs are safe, if
there is no report of people death and of efficacy, if people get relief from it. On the other hand, government
laboratories check for presence of therapeutic agent in samples in the right amount and consider this checking
sufficient to declare that we have safe and efficacious drug. All the reasons exist to suggest that the both
assumptions are nothing but myths.
It is as simple as if someone could understand that why dozens of times lower price drug is not imported by
United Kingdom (UK) whereas, it is tested in UK laboratories and found of standard quality. The Governments
especially Punjab Government while neglecting the
fundamental affairs of regulatory science is spending a
disproportional amount of public money and putting
extensive resources into drug testing. There is no
regulatory impact analysis (RIA) document available to
justify such unrealistic expenditure. It would have been
very good to hear from real subject matter experts instead
of experts of other professions and RIA should have been carefully done well before time. However, it is not too
late to respect the tools of modern science, come out from ego and do the best with all honesty.
For the sake of clarity, let’s take a scenario as an example where food stuff being cooked on roadside in an open
environment and in a five star hotel kitchen. Remember that the material, chef and the recipe are same in both
cases. Upon testing of samples from both food stuff, if a piece of hair is found in stuff coming from a five star
hotel while there is no issue in the sample of stuff coming from roadside, how would you deal with them? Surely
your trust will not breach on a five star hotel and you will treat presence of hair as an isolated incident that may be
covered under residual margin of error. On the other hand, if you declare food stuff of roadside as a standard
quality and allow using for a large population, there is no need to comment further on wisdom. On the presence of
hair, if we accuse the five star hotels and pull up in the court process, it would be unreasonable, worst and
inconsistent with the fundamental approach of regulatory sciences.
If someone could understand that why
dozens of times lower price drug is not
imported by United Kingdom (UK)
whereas, it is tested in UK laboratories
and found of standard quality.
Can Quality of Drug be assured through Testing in Government Laboratories? Page 2 of 4
Obaid Ali & Roohi B. Obaid Karachi the 20th
Nov 2017
Be aware that the writers are talking about the drug product taken to save the precious life of human beings.
Equipment, manufacturing process, quality of raw materials used to manufacture one similar product are not
exactly same in different industries. To demonstrate that someone is capable to manufacture quality drug requires
a lot of scientific studies and data that is certainly reviewed by number of different experts from regulatory
authority to decide its reasonable equivalency in therapeutic effect within acceptable bracket of consumer safety
and other claims conclusively in the interest of protection and advancement of public health.
It was a time long ago when extensive testing was relied upon, to guarantee a quality drug and all the quality
affairs revolved around classical tool (Testing). Later on with the experience and expanding knowledge, it came to
bright that the manufacturing process have a greater impact on drug quality, hence, in-process controls were
introduced and they became the part of the regulation. Further
moving upward on the ladder of age, the limitations of sampling
was realized in representing the whole batch. Moreover, the
limitations of testing surfaced and established that testing of 20
units of a batch consisting of millions of units cannot assure the
quality of every unit of the batch. Resultantly, emphasis was
extended, reshaped and focused more on the product
development, process understanding and control strategy to
achieve consistency within a batch, time after time and batch
after batch. Studies conducted by hospitals to collect the
evidence of clinical outcome among different generics or between generic and innovator may not give sound
scientific strength to decide drug equivalency or its associated safety. For example, if you judge the quality of a
perfume by its smell, you may not be able to conclude its life span, impurities it carry etc. and sometimes this
approach might end up in disaster (a lot of examples that took lives of individuals have already been experienced
by this world).
Independent and integrated regulatory reviews under Good Review Practices (GRP) as well as regulatory
inspections of manufacturing sites under Good Manufacturing Practices (GMP) standards to determine the
strength of product and manufacturing capacity are indispensible. So, without understanding the entire
manufacturing process and mechanism to keep controls efficient throughout the manufacturing, no one will be
able to say that drug is consistent in the entire batch in terms of purity, right dose and right delivery of drug inside
the body and is without unreasonable contamination of germs, particles and traces of other drugs. Such oversight
also ensures elimination of any potential mix up with other drug, same drug of different strength or with sorted
(defective) drug during the each and every step of the manufacturing and distribution process until it reaches to
the patient.
Testing of 20 units of a
batch consisting of
millions of units cannot
assure the quality of every
unit of the batch.
Can Quality of Drug be assured through Testing in Government Laboratories? Page 3 of 4
Obaid Ali & Roohi B. Obaid Karachi the 20th
Nov 2017
It is necessary to be abreast of the fundamental dimensions that categorically spell time and again about
limitations of compendia procedures of testing. In most instances testing is done on a small sample of a batch (for
example, a drug manufacturer may test 100 tablets from a batch that contains 2 million tablets), so that most of the
batch can be used for patients rather than destroyed by testing. Therefore, it is important that drugs are
manufactured under conditions and practices required by the GMP regulations to assure that quality is built into
the design and manufacturing process at every step. Facilities that are in good condition, equipment that is
properly maintained and calibrated, employees who are qualified and fully trained, and processes that are reliable
and reproducible, are a few examples of how GMP requirements help to assure the safety and efficacy of drug
products. Let us take another example of injectable products which are supposed to be free from microorganism
known as sterility test. It should be recognized that the referee
sterility test might not detect microbial contamination, if present in
only a small percentage of the finished articles in the lot because the
specified number of units to be taken impose a significant statistical
limitation on the utility of the test results. Global Bible of testing of
drugs (Pharmacopoeia) itself state that these procedures are not by
themselves designed to ensure that a batch of product is sterile or
has been sterilized. A state of sterility assurance can be established
only through the use of validated sterilization process or aseptic
processing, if any, under appropriate GMP and not by reliance
solely on sterility testing.
The intent of this article is not to eliminate the role of regulatory
laboratory in the quality oversight but need to understand its
inherent limitations. The largest leading regulatory authority of the
world, United States-Food and Drug Administration (US-FDA)
having a dozen of state of art and fully equipped qualified testing
facilities across the USA, tested about 4000 drugs in 10 years. The
selection criteria of product start from complaint pattern about reduced effectiveness to whistle blowing of
internal (regulators) or external (scientists) experts. Sometimes GMP concerns and potency concerns of certain
drugs require attention for specific testing. The most prescribed drugs and first generic versions are also covered
under priority. US-FDA's laboratories found 1.1% of the drug products in 10 years to be deviated from the
acceptable standards and found out of specification (OOS). Responsible managements were given hands for
assistance in timely improvement to avoid any unreasonable drug shortage. Voluntary pursuance to go for root
cause analysis, corrective and preventive action always remain action of choice instead of opting and imposing
regulatory or enforcement actions. In the light of facts described here diversion towards criminal proceedings or
misuse of power upon OOS results in Pakistan may be reviewed by looking at the data of modern world that is
being emerged with super science.
We have a lot of
experience to see
graveyard of scientific
instrument in public
sector. Till date neither
World Health
Organization (WHO) nor
any other international
agency recognizes any
Government laboratory of
Pakistan for testing of
drugs giving credible
results.
Can Quality of Drug be assured through Testing in Government Laboratories? Page 4 of 4
Obaid Ali & Roohi B. Obaid Karachi the 20th
Nov 2017
The important issue of the laboratory is the reliability of the results, their reproducibility upon retesting in the
same laboratory or other laboratory and auditability to back trace the data reaching to the conclusion for its
integrity. Beautifying the buildings and investment in equipment may give an aesthetic sense of development to
the common people but has no role in credibility of the results unless the systems are based on sound science. It is
very unfortunate to see the government
laboratories purchasing ruthlessly innovative
and highly sensitive equipment, while people
are not trained to drive and operate them. It is
as simple to elucidate the event that you buy
modern Mercedes car and allow someone to
learn driving on it, who does not know to drive a car before. We have a lot of experience to see graveyard of
scientific instrument in public sector. Till date neither World Health Organization (WHO) nor any other
international agency recognizes any Government laboratory of Pakistan for testing of drugs giving credible
results. Even countries of the North African region qualify WHO standards and are included in their list available
on the WHO website. From last four years, authorities have attempted to deceive the public consistently through
publication of false news and testimony before the Parliament that their laboratory is about to be qualified by
WHO.
It should be straight, simple and clear that the quality of medicines available in Pakistan could not yet gain respect
from any reference or world leading countries. There is no report available to exhibit or prove the quality (product
manufactured here in Pakistan, no matter it is from corporate giant or national small business) as per the standards
set down in the 21st
century. Knowingly or unknowingly use and promotion of government laboratories data about
quality of drug available in market is indeed a false perception. Remember and please be aware that regulatory
science is not so simple and small but complex and will be more challenging in the days to come. To ensure
public safety and quality of drug, we have no way left other than to enhance capacity of learning, de-learning and
relearning that could make our walk compatible with the modern science and get it trusted all around
Obaid Ali, R. Ph., M. Phil., Ph. D. Roohi B. Obaid, R. Ph., M. Phil.
Disclaimer: It is purely personal point of view written in the best of professional knowledge and experience of dealing with affairs of
regulatory sciences as Federal Regulator. In any way, it is not an obligation to agree by the organization or association to which we
belong. The intent of writing is to sensitize culture of reading, learning, arguing and writing. Feedback: All critics, comments and
questions will be welcome on obaidali1971@gmail.com (Nov 20th
2017)
To ensure public safety and quality of drug, we
have no way left other than to enhance capacity
of learning, de-learning and relearning that could
make our walk compatible with the modern
science and get it trusted all around.

Contenu connexe

Tendances

Process of new drug development & approval
Process of new drug development & approvalProcess of new drug development & approval
Process of new drug development & approvalDr. Marya Ahsan
 
nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of crRohit K.
 
Non clinical drug development
Non clinical drug developmentNon clinical drug development
Non clinical drug developmentAbhimanyu Awasthi
 
Introduction to Pre-clinical Trials
Introduction to Pre-clinical TrialsIntroduction to Pre-clinical Trials
Introduction to Pre-clinical TrialsGargi Nanda
 
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...NAMSA
 
RyMat Drug Development Training Module
RyMat Drug Development Training ModuleRyMat Drug Development Training Module
RyMat Drug Development Training ModuleStuart Silverman
 
An overview of Drug Discovery and Development Process
An overview of Drug Discovery and Development ProcessAn overview of Drug Discovery and Development Process
An overview of Drug Discovery and Development ProcessTulsi Gulabrao Patil
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueRobert Sturm
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process KerentechEstherMM
 
6. drug design and development
6. drug design and development6. drug design and development
6. drug design and developmentBruno Mmassy
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
 
Good laboratory practice
Good laboratory practiceGood laboratory practice
Good laboratory practiceManjuJhakhar
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
 
Drug approval process
Drug approval processDrug approval process
Drug approval processLitashaGandhi
 
Overcoming challenges in Drug Development
Overcoming challenges in Drug DevelopmentOvercoming challenges in Drug Development
Overcoming challenges in Drug DevelopmentCharles Oo
 
Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.rkreddy98666
 
FDA drug approval and review process
FDA drug approval and review processFDA drug approval and review process
FDA drug approval and review processNIGAR FATIMA
 

Tendances (20)

Process of new drug development & approval
Process of new drug development & approvalProcess of new drug development & approval
Process of new drug development & approval
 
Quality assuarance
Quality assuaranceQuality assuarance
Quality assuarance
 
nda and phases of cr
nda and phases of crnda and phases of cr
nda and phases of cr
 
Non clinical drug development
Non clinical drug developmentNon clinical drug development
Non clinical drug development
 
Drug discovery
Drug discovery Drug discovery
Drug discovery
 
Introduction to Pre-clinical Trials
Introduction to Pre-clinical TrialsIntroduction to Pre-clinical Trials
Introduction to Pre-clinical Trials
 
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...
ISO 10993-3: Biological Evaluation of Medical Devices - Tests for Genotoxicit...
 
RyMat Drug Development Training Module
RyMat Drug Development Training ModuleRyMat Drug Development Training Module
RyMat Drug Development Training Module
 
Preclinical studies
Preclinical studiesPreclinical studies
Preclinical studies
 
An overview of Drug Discovery and Development Process
An overview of Drug Discovery and Development ProcessAn overview of Drug Discovery and Development Process
An overview of Drug Discovery and Development Process
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and Revenue
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process Kerentech
 
6. drug design and development
6. drug design and development6. drug design and development
6. drug design and development
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.
 
Good laboratory practice
Good laboratory practiceGood laboratory practice
Good laboratory practice
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
Drug approval process
Drug approval processDrug approval process
Drug approval process
 
Overcoming challenges in Drug Development
Overcoming challenges in Drug DevelopmentOvercoming challenges in Drug Development
Overcoming challenges in Drug Development
 
Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.
 
FDA drug approval and review process
FDA drug approval and review processFDA drug approval and review process
FDA drug approval and review process
 

Similaire à Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testing in Government Laboratories

Pharmaceutical product development and its associated quality system 01
Pharmaceutical product development and its associated quality system 01Pharmaceutical product development and its associated quality system 01
Pharmaceutical product development and its associated quality system 01Abdirizak Mohammed
 
The Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryThe Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryVarsha Chauhan
 
BioEntrepreneurship: Navigating the Global Regulatory Pathway
BioEntrepreneurship: Navigating the Global Regulatory Pathway BioEntrepreneurship: Navigating the Global Regulatory Pathway
BioEntrepreneurship: Navigating the Global Regulatory Pathway MaRS Discovery District
 
Accelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAccelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAnthony Melvin Crasto Ph.D
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIJafarali Masi
 
Emergence of Enhanced Quality Expectations in Pharmaceuticals
Emergence of Enhanced Quality Expectations in PharmaceuticalsEmergence of Enhanced Quality Expectations in Pharmaceuticals
Emergence of Enhanced Quality Expectations in PharmaceuticalsObaid Ali / Roohi B. Obaid
 
Centre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfCentre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfObaid Ali / Roohi B. Obaid
 
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Obaid Ali / Roohi B. Obaid
 
Quality control of pharmaceutical products
Quality control of pharmaceutical productsQuality control of pharmaceutical products
Quality control of pharmaceutical productsSiham Abdallaha
 
Quality control of pharmaceuticals
Quality control of pharmaceuticalsQuality control of pharmaceuticals
Quality control of pharmaceuticalsSiham Abdallaha
 
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...BOC Sciences
 
The stages of Drug Discovery and Development process
The stages of Drug Discovery and Development processThe stages of Drug Discovery and Development process
The stages of Drug Discovery and Development processA M O L D E O R E
 
Investigation New Drug Application
Investigation New Drug ApplicationInvestigation New Drug Application
Investigation New Drug ApplicationJessica Huston
 
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...ClinosolIndia
 
Drug development process
Drug development processDrug development process
Drug development processPawanDhamala1
 

Similaire à Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testing in Government Laboratories (20)

Confidence on Generics.pdf
Confidence on Generics.pdfConfidence on Generics.pdf
Confidence on Generics.pdf
 
Generic Drug Performance
Generic Drug PerformanceGeneric Drug Performance
Generic Drug Performance
 
Pharmaceutical product development and its associated quality system 01
Pharmaceutical product development and its associated quality system 01Pharmaceutical product development and its associated quality system 01
Pharmaceutical product development and its associated quality system 01
 
The Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals IndustryThe Role of clinical Research in Pharmaceuticals Industry
The Role of clinical Research in Pharmaceuticals Industry
 
BioEntrepreneurship: Navigating the Global Regulatory Pathway
BioEntrepreneurship: Navigating the Global Regulatory Pathway BioEntrepreneurship: Navigating the Global Regulatory Pathway
BioEntrepreneurship: Navigating the Global Regulatory Pathway
 
Accelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony CrastoAccelerating Generic Approvals by Dr Anthony Crasto
Accelerating Generic Approvals by Dr Anthony Crasto
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy II
 
Pharma Asia Newsletter Launched
Pharma Asia Newsletter LaunchedPharma Asia Newsletter Launched
Pharma Asia Newsletter Launched
 
Emergence of Enhanced Quality Expectations in Pharmaceuticals
Emergence of Enhanced Quality Expectations in PharmaceuticalsEmergence of Enhanced Quality Expectations in Pharmaceuticals
Emergence of Enhanced Quality Expectations in Pharmaceuticals
 
Training on "GMP of the 21st Century"
Training on "GMP of the 21st Century"Training on "GMP of the 21st Century"
Training on "GMP of the 21st Century"
 
Centre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdfCentre for Quality Sciences-Information File-2024.pdf
Centre for Quality Sciences-Information File-2024.pdf
 
Development of drug
Development of drugDevelopment of drug
Development of drug
 
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
Cultural Relationship between Quality of Drugs and Prevailing Regulatory Envi...
 
Quality control of pharmaceutical products
Quality control of pharmaceutical productsQuality control of pharmaceutical products
Quality control of pharmaceutical products
 
Quality control of pharmaceuticals
Quality control of pharmaceuticalsQuality control of pharmaceuticals
Quality control of pharmaceuticals
 
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...
BOC Sciences Updated Its Product Catalog of Pharmaceutical Impurity Reference...
 
The stages of Drug Discovery and Development process
The stages of Drug Discovery and Development processThe stages of Drug Discovery and Development process
The stages of Drug Discovery and Development process
 
Investigation New Drug Application
Investigation New Drug ApplicationInvestigation New Drug Application
Investigation New Drug Application
 
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
 
Drug development process
Drug development processDrug development process
Drug development process
 

Plus de Obaid Ali / Roohi B. Obaid

A Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsA Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsObaid Ali / Roohi B. Obaid
 
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfDemonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfObaid Ali / Roohi B. Obaid
 
Track, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfTrack, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfObaid Ali / Roohi B. Obaid
 
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdfObaid Ali / Roohi B. Obaid
 
Judging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineJudging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineObaid Ali / Roohi B. Obaid
 

Plus de Obaid Ali / Roohi B. Obaid (20)

A Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological ProductsA Strategic Talk on Biologicals & Biotechnological Products
A Strategic Talk on Biologicals & Biotechnological Products
 
A Tragic Resistance to Learn.pdf
A Tragic Resistance to Learn.pdfA Tragic Resistance to Learn.pdf
A Tragic Resistance to Learn.pdf
 
230930.pdf
230930.pdf230930.pdf
230930.pdf
 
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdfDemonstrate your QMS during Inspection-30 Sep 2023.pdf
Demonstrate your QMS during Inspection-30 Sep 2023.pdf
 
Track, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdfTrack, Trace & Understand Science of Life from Real World Evidence.pdf
Track, Trace & Understand Science of Life from Real World Evidence.pdf
 
Neurotoxicity & Neurodegenaration.pdf
Neurotoxicity & Neurodegenaration.pdfNeurotoxicity & Neurodegenaration.pdf
Neurotoxicity & Neurodegenaration.pdf
 
Application of Data & AI in Pharma 4
Application of Data & AI in Pharma 4Application of Data & AI in Pharma 4
Application of Data & AI in Pharma 4
 
PICS-ICH
PICS-ICHPICS-ICH
PICS-ICH
 
Quality Affairs of Pharmaceuticals
Quality Affairs of PharmaceuticalsQuality Affairs of Pharmaceuticals
Quality Affairs of Pharmaceuticals
 
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
120th Training Session - Unfortunate Wave of DEG Tragedy.pdf
 
CQS Session - RO - 16 Oct 2022.pdf
CQS Session - RO - 16 Oct 2022.pdfCQS Session - RO - 16 Oct 2022.pdf
CQS Session - RO - 16 Oct 2022.pdf
 
GMP Session for Professional Development.pdf
GMP Session for Professional Development.pdfGMP Session for Professional Development.pdf
GMP Session for Professional Development.pdf
 
Q & A - June - Sep 2022.pdf
Q & A - June - Sep 2022.pdfQ & A - June - Sep 2022.pdf
Q & A - June - Sep 2022.pdf
 
Judging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the LineJudging Science & Prior Knowledge Beyond the Line
Judging Science & Prior Knowledge Beyond the Line
 
Maturing Drug Quality to Deliver Promise
Maturing Drug Quality to Deliver PromiseMaturing Drug Quality to Deliver Promise
Maturing Drug Quality to Deliver Promise
 
PQRS 2022 - Education
PQRS  2022 - EducationPQRS  2022 - Education
PQRS 2022 - Education
 
4 - GMP June 2022 - CQS.pdf
4 - GMP June 2022 - CQS.pdf4 - GMP June 2022 - CQS.pdf
4 - GMP June 2022 - CQS.pdf
 
3 - GMP June 2022 - CQS.pdf
3 - GMP June 2022 - CQS.pdf3 - GMP June 2022 - CQS.pdf
3 - GMP June 2022 - CQS.pdf
 
2 - GMP June 2022 - CQS.pdf
2 - GMP June 2022 - CQS.pdf2 - GMP June 2022 - CQS.pdf
2 - GMP June 2022 - CQS.pdf
 
1 - GMP June 2022 - CQS.pdf
1 - GMP June 2022 - CQS.pdf1 - GMP June 2022 - CQS.pdf
1 - GMP June 2022 - CQS.pdf
 

Dernier

A3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingA3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingCIToolkit
 
Analyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingAnalyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingCIToolkit
 
Roadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint PresentationRoadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint Presentationgdscghrcem
 
Tackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanTackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanStefan Wolpers
 
An Important Step Toward Process Improvement
An Important Step Toward Process ImprovementAn Important Step Toward Process Improvement
An Important Step Toward Process ImprovementCIToolkit
 
Organizations in a Future with Generative AI
Organizations in a Future with Generative AIOrganizations in a Future with Generative AI
Organizations in a Future with Generative AIKye Andersson
 
What is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfWhat is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfBALASUNDARESAN M
 
HR for Non HR_Learning and Development.
HR for Non HR_Learning  and Development.HR for Non HR_Learning  and Development.
HR for Non HR_Learning and Development.azischin
 
From Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMFrom Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMGloria Chow
 
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...AgileNetwork
 
Value Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationValue Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationCIToolkit
 
Test_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenTest_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenolgaz9
 
The Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectThe Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectCIToolkit
 
Empowering Resilience & Strategic Growth: Insights for Emerging Leaders
Empowering Resilience & Strategic Growth: Insights for Emerging LeadersEmpowering Resilience & Strategic Growth: Insights for Emerging Leaders
Empowering Resilience & Strategic Growth: Insights for Emerging LeadersMahmoud Rabie
 
Making Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsMaking Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsCIToolkit
 
Forget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsForget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsStephan Koning
 
Improving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksImproving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksCIToolkit
 
How the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioHow the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioChristopher Totten
 
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementApplying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementCIToolkit
 

Dernier (20)

A3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem SolvingA3 Thinking: A Structured Approach to Problem Solving
A3 Thinking: A Structured Approach to Problem Solving
 
Analyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value MappingAnalyzing and Monitoring Processes through Time Value Mapping
Analyzing and Monitoring Processes through Time Value Mapping
 
Roadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint PresentationRoadway to GDSC- Session 1 Powerpoint Presentation
Roadway to GDSC- Session 1 Powerpoint Presentation
 
Tackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna RothmanTackling Fake Agility w/ Johanna Rothman
Tackling Fake Agility w/ Johanna Rothman
 
An Important Step Toward Process Improvement
An Important Step Toward Process ImprovementAn Important Step Toward Process Improvement
An Important Step Toward Process Improvement
 
Organizations in a Future with Generative AI
Organizations in a Future with Generative AIOrganizations in a Future with Generative AI
Organizations in a Future with Generative AI
 
What is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdfWhat is 5S principles of trainers for training institutions.pdf
What is 5S principles of trainers for training institutions.pdf
 
HR for Non HR_Learning and Development.
HR for Non HR_Learning  and Development.HR for Non HR_Learning  and Development.
HR for Non HR_Learning and Development.
 
From Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EMFrom Command Line to Reporting Line: The Diary of a First-Time EM
From Command Line to Reporting Line: The Diary of a First-Time EM
 
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
ANIn Coimbatore March 2024 | Agile & AI in Project Management by Dhilipkumar ...
 
Value Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process OptimizationValue Stream Map: A Visual Approach to Process Optimization
Value Stream Map: A Visual Approach to Process Optimization
 
Test_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteenTest_document_upload_SQL_minimum_fourteen
Test_document_upload_SQL_minimum_fourteen
 
The Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and EffectThe Role of Fishbone Diagram in Analyzing Cause and Effect
The Role of Fishbone Diagram in Analyzing Cause and Effect
 
Empowering Resilience & Strategic Growth: Insights for Emerging Leaders
Empowering Resilience & Strategic Growth: Insights for Emerging LeadersEmpowering Resilience & Strategic Growth: Insights for Emerging Leaders
Empowering Resilience & Strategic Growth: Insights for Emerging Leaders
 
Capacity2 - Briefing and Facilitation training slides
Capacity2 - Briefing and Facilitation training slidesCapacity2 - Briefing and Facilitation training slides
Capacity2 - Briefing and Facilitation training slides
 
Making Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity DiagramsMaking Sense of Multiple Ideas with Affinity Diagrams
Making Sense of Multiple Ideas with Affinity Diagrams
 
Forget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outsForget Fiverr : Fractional Employment the ins and outs
Forget Fiverr : Fractional Employment the ins and outs
 
Improving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba WalksImproving Operations through Observation and Gemba Walks
Improving Operations through Observation and Gemba Walks
 
How the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the StudioHow the Heck do you Teach Level Design? Educating in the Studio
How the Heck do you Teach Level Design? Educating in the Studio
 
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous ImprovementApplying the PDCA Cycle: A Blueprint for Continuous Improvement
Applying the PDCA Cycle: A Blueprint for Continuous Improvement
 

Pakistan's Regulatory Approach: Can Quality of Drug be assured through Testing in Government Laboratories

  • 1. Pakistan’s Regulatory Approach Can Quality of Drug be assured through Testing in Government Laboratories? Obaid Ali & Roohi B. Obaid Planting quality in manufacturing of drugs and its secure delivery to the patient is a real challenge and remains a concern all around. Inability of the intellectuals and Government leadership (Federal Government, generally Provincial Governments and particularly the Punjab Government) to understand the phenomenon of drug quality is certainly amazing and a reason of great distress for real professionals. It is considered that drugs are safe, if there is no report of people death and of efficacy, if people get relief from it. On the other hand, government laboratories check for presence of therapeutic agent in samples in the right amount and consider this checking sufficient to declare that we have safe and efficacious drug. All the reasons exist to suggest that the both assumptions are nothing but myths. It is as simple as if someone could understand that why dozens of times lower price drug is not imported by United Kingdom (UK) whereas, it is tested in UK laboratories and found of standard quality. The Governments especially Punjab Government while neglecting the fundamental affairs of regulatory science is spending a disproportional amount of public money and putting extensive resources into drug testing. There is no regulatory impact analysis (RIA) document available to justify such unrealistic expenditure. It would have been very good to hear from real subject matter experts instead of experts of other professions and RIA should have been carefully done well before time. However, it is not too late to respect the tools of modern science, come out from ego and do the best with all honesty. For the sake of clarity, let’s take a scenario as an example where food stuff being cooked on roadside in an open environment and in a five star hotel kitchen. Remember that the material, chef and the recipe are same in both cases. Upon testing of samples from both food stuff, if a piece of hair is found in stuff coming from a five star hotel while there is no issue in the sample of stuff coming from roadside, how would you deal with them? Surely your trust will not breach on a five star hotel and you will treat presence of hair as an isolated incident that may be covered under residual margin of error. On the other hand, if you declare food stuff of roadside as a standard quality and allow using for a large population, there is no need to comment further on wisdom. On the presence of hair, if we accuse the five star hotels and pull up in the court process, it would be unreasonable, worst and inconsistent with the fundamental approach of regulatory sciences. If someone could understand that why dozens of times lower price drug is not imported by United Kingdom (UK) whereas, it is tested in UK laboratories and found of standard quality.
  • 2. Can Quality of Drug be assured through Testing in Government Laboratories? Page 2 of 4 Obaid Ali & Roohi B. Obaid Karachi the 20th Nov 2017 Be aware that the writers are talking about the drug product taken to save the precious life of human beings. Equipment, manufacturing process, quality of raw materials used to manufacture one similar product are not exactly same in different industries. To demonstrate that someone is capable to manufacture quality drug requires a lot of scientific studies and data that is certainly reviewed by number of different experts from regulatory authority to decide its reasonable equivalency in therapeutic effect within acceptable bracket of consumer safety and other claims conclusively in the interest of protection and advancement of public health. It was a time long ago when extensive testing was relied upon, to guarantee a quality drug and all the quality affairs revolved around classical tool (Testing). Later on with the experience and expanding knowledge, it came to bright that the manufacturing process have a greater impact on drug quality, hence, in-process controls were introduced and they became the part of the regulation. Further moving upward on the ladder of age, the limitations of sampling was realized in representing the whole batch. Moreover, the limitations of testing surfaced and established that testing of 20 units of a batch consisting of millions of units cannot assure the quality of every unit of the batch. Resultantly, emphasis was extended, reshaped and focused more on the product development, process understanding and control strategy to achieve consistency within a batch, time after time and batch after batch. Studies conducted by hospitals to collect the evidence of clinical outcome among different generics or between generic and innovator may not give sound scientific strength to decide drug equivalency or its associated safety. For example, if you judge the quality of a perfume by its smell, you may not be able to conclude its life span, impurities it carry etc. and sometimes this approach might end up in disaster (a lot of examples that took lives of individuals have already been experienced by this world). Independent and integrated regulatory reviews under Good Review Practices (GRP) as well as regulatory inspections of manufacturing sites under Good Manufacturing Practices (GMP) standards to determine the strength of product and manufacturing capacity are indispensible. So, without understanding the entire manufacturing process and mechanism to keep controls efficient throughout the manufacturing, no one will be able to say that drug is consistent in the entire batch in terms of purity, right dose and right delivery of drug inside the body and is without unreasonable contamination of germs, particles and traces of other drugs. Such oversight also ensures elimination of any potential mix up with other drug, same drug of different strength or with sorted (defective) drug during the each and every step of the manufacturing and distribution process until it reaches to the patient. Testing of 20 units of a batch consisting of millions of units cannot assure the quality of every unit of the batch.
  • 3. Can Quality of Drug be assured through Testing in Government Laboratories? Page 3 of 4 Obaid Ali & Roohi B. Obaid Karachi the 20th Nov 2017 It is necessary to be abreast of the fundamental dimensions that categorically spell time and again about limitations of compendia procedures of testing. In most instances testing is done on a small sample of a batch (for example, a drug manufacturer may test 100 tablets from a batch that contains 2 million tablets), so that most of the batch can be used for patients rather than destroyed by testing. Therefore, it is important that drugs are manufactured under conditions and practices required by the GMP regulations to assure that quality is built into the design and manufacturing process at every step. Facilities that are in good condition, equipment that is properly maintained and calibrated, employees who are qualified and fully trained, and processes that are reliable and reproducible, are a few examples of how GMP requirements help to assure the safety and efficacy of drug products. Let us take another example of injectable products which are supposed to be free from microorganism known as sterility test. It should be recognized that the referee sterility test might not detect microbial contamination, if present in only a small percentage of the finished articles in the lot because the specified number of units to be taken impose a significant statistical limitation on the utility of the test results. Global Bible of testing of drugs (Pharmacopoeia) itself state that these procedures are not by themselves designed to ensure that a batch of product is sterile or has been sterilized. A state of sterility assurance can be established only through the use of validated sterilization process or aseptic processing, if any, under appropriate GMP and not by reliance solely on sterility testing. The intent of this article is not to eliminate the role of regulatory laboratory in the quality oversight but need to understand its inherent limitations. The largest leading regulatory authority of the world, United States-Food and Drug Administration (US-FDA) having a dozen of state of art and fully equipped qualified testing facilities across the USA, tested about 4000 drugs in 10 years. The selection criteria of product start from complaint pattern about reduced effectiveness to whistle blowing of internal (regulators) or external (scientists) experts. Sometimes GMP concerns and potency concerns of certain drugs require attention for specific testing. The most prescribed drugs and first generic versions are also covered under priority. US-FDA's laboratories found 1.1% of the drug products in 10 years to be deviated from the acceptable standards and found out of specification (OOS). Responsible managements were given hands for assistance in timely improvement to avoid any unreasonable drug shortage. Voluntary pursuance to go for root cause analysis, corrective and preventive action always remain action of choice instead of opting and imposing regulatory or enforcement actions. In the light of facts described here diversion towards criminal proceedings or misuse of power upon OOS results in Pakistan may be reviewed by looking at the data of modern world that is being emerged with super science. We have a lot of experience to see graveyard of scientific instrument in public sector. Till date neither World Health Organization (WHO) nor any other international agency recognizes any Government laboratory of Pakistan for testing of drugs giving credible results.
  • 4. Can Quality of Drug be assured through Testing in Government Laboratories? Page 4 of 4 Obaid Ali & Roohi B. Obaid Karachi the 20th Nov 2017 The important issue of the laboratory is the reliability of the results, their reproducibility upon retesting in the same laboratory or other laboratory and auditability to back trace the data reaching to the conclusion for its integrity. Beautifying the buildings and investment in equipment may give an aesthetic sense of development to the common people but has no role in credibility of the results unless the systems are based on sound science. It is very unfortunate to see the government laboratories purchasing ruthlessly innovative and highly sensitive equipment, while people are not trained to drive and operate them. It is as simple to elucidate the event that you buy modern Mercedes car and allow someone to learn driving on it, who does not know to drive a car before. We have a lot of experience to see graveyard of scientific instrument in public sector. Till date neither World Health Organization (WHO) nor any other international agency recognizes any Government laboratory of Pakistan for testing of drugs giving credible results. Even countries of the North African region qualify WHO standards and are included in their list available on the WHO website. From last four years, authorities have attempted to deceive the public consistently through publication of false news and testimony before the Parliament that their laboratory is about to be qualified by WHO. It should be straight, simple and clear that the quality of medicines available in Pakistan could not yet gain respect from any reference or world leading countries. There is no report available to exhibit or prove the quality (product manufactured here in Pakistan, no matter it is from corporate giant or national small business) as per the standards set down in the 21st century. Knowingly or unknowingly use and promotion of government laboratories data about quality of drug available in market is indeed a false perception. Remember and please be aware that regulatory science is not so simple and small but complex and will be more challenging in the days to come. To ensure public safety and quality of drug, we have no way left other than to enhance capacity of learning, de-learning and relearning that could make our walk compatible with the modern science and get it trusted all around Obaid Ali, R. Ph., M. Phil., Ph. D. Roohi B. Obaid, R. Ph., M. Phil. Disclaimer: It is purely personal point of view written in the best of professional knowledge and experience of dealing with affairs of regulatory sciences as Federal Regulator. In any way, it is not an obligation to agree by the organization or association to which we belong. The intent of writing is to sensitize culture of reading, learning, arguing and writing. Feedback: All critics, comments and questions will be welcome on obaidali1971@gmail.com (Nov 20th 2017) To ensure public safety and quality of drug, we have no way left other than to enhance capacity of learning, de-learning and relearning that could make our walk compatible with the modern science and get it trusted all around.